Skip to Content
Find out more about colorectal cancer treatments

Octreotide Pregnancy and Breastfeeding Warnings

Octreotide is also known as: Sandostatin, Sandostatin LAR Depot

Octreotide Pregnancy Warnings

Use is not recommended unless clearly needed. AU TGA pregnancy category: C US FDA pregnancy category: B Comments: -Use of this product could potentially restore fertility in women with acromegaly. -Advise females of childbearing potential to use adequate contraception.

Animal studies at doses up to 16 times the recommended human dose have shown no fetal harm, although fetal and post-natal growth retardation was seen. There are no controlled data in human pregnancy. A limited number of pregnancy exposures resulted in mostly normal newborns, and no cases of congenital anomalies or malformations, however there were several spontaneous abortions during the first trimester. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Octreotide Breastfeeding Warnings

Breastfeeding is not recommended during use of this drug. Excreted into human milk: Unknown Excreted into animal milk: Yes

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. SandoSTATIN LAR Depot (octreotide)." Novartis Consumer Health, Parsippany, NJ.
  4. "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.

References for breastfeeding information

  1. "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  2. "Product Information. SandoSTATIN LAR Depot (octreotide)." Novartis Consumer Health, Parsippany, NJ.
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide